癌症基因组图谱分型免疫组化在子宫内膜样癌中的应用

Objective To explore the clinical application value of cancer genome atlas(TCGA) molecular classification immunohistochemical detection in endometrioid carcinoma. Methods This study analyzed 60 endometrioid classification patients treated surgically at Dongguan Kanghua Hospital between January 2023 and June 2025. All patients underwent immunohistochemical testing. Based on the TCGA endometrial carcinoma molecular classification criteria and combined with immunohistochemical results, patients were categorized into distinct molecular subtypes. The research compared pathological types, lymphangio-gap invasion, lymph node metastasis, mismatch repair(MMR) protein positivity rates, and p53 protein positivity rates among different subtypes, while also conducting correlation analysis between selected indicators. Results The 60 endometrioid carcinoma cases included 18 with MMRd mutation, 19 with p53 mutation, 23 with p53 wild-type, and no POLE mutation was observed. No significant differences were observed in pathological types, lymphangio-gap invasion, or lymph node metastasis among subtypes(P>0.05). There were statistically significant differences in the positive expression rates of MMR proteins and p53 proteins among the three subtypes(P<0.05). Correlation analysis revealed that TCGA molecular subtyping was not association with lymphangio-gap invasion or lymph node metastasis in patients with endometrioid carcinoma(P>0.05), but significant correlations were observed with MMR protein, p53 protein(P<0.05). Conclusion Simplified TCGA molecular classification based on immunohistochemical results provides objective diagnostic references for endometrioid carcinoma and enables prognostic prediction.